2nd T-Cell Engager for Autoimmune Disease Summit [10/27/26]

Accelerate the Development of T-Cell Engagers in Autoimmune Diseases by Expanding Targets Beyond B-Cells, Reducing CRS Toxicities, and Achieve Deep Depletion and Clinical Success

The 2nd T-Cell Engager for Autoimmune Disease Summit arrives at a pivotal moment for the field as autoimmune TCEs rapidly transition from oncology-inspired concepts into one of the industry’s most exciting and heavily invested therapeutic modalities. Following major investments and partnerships from companies including Gilead, UCB, Sanofi, and Boehringer Ingelheim, the focus has shifted from proving the modality works to optimizing safety, durability, and clinical differentiation.

As the industry’s only dedicated meeting focused exclusively on autoimmune T-cell engagers, this summit brings together 80+ leaders across discovery, translational, preclinical, clinical, and business development to tackle the field’s most urgent challenges. Discussions will explore how to reduce CRS toxicities, improve tissue-selective immune depletion, engineer next-generation engager architectures, expand beyond B-cell targets, and translate early clinical insights into safer, more effective therapies.

With 15+ new speakers, emerging clinical datasets, 2 deep-dive workshops, and 8+ hours of networking including speed networking and interactive roundtables, this is the must-attend forum to benchmark strategies, build partnerships, and shape the future of autoimmune T-cell engager development.

URLs:

Tickets: https://go.evvnt.com/3731311-2?pid=5248

Brochure: https://go.evvnt.com/3731311-3?pid=5248

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:

Primary - Conference + Workshop Day: USD 4397.00,

Primary - Conference Only: USD 3099.00,

Academic - Conference + Workshop Day: USD 3797.00,

Academic - Conference Only: USD 2699.00,

Vendor - Conference + Workshop Day: USD 5397.00,

Vendor - Conference Only: USD 3899.00

Speakers: Mike Liao, Vice President of Clinical Pharmacology, Third Arc Bio, Sarah leonard, Chief Executive Officer, T-Cypher Bio, Jonathan Hill, Vice President and Head, Research, Synolo Therapeutics, Elaine Chen, Senior Scientist, Translational Biology, Rondo Therapeutics, David de Graaf, Co-Founder, CEO and President, Reverb Therapeutics Inc., Tapan Maniar, Chief Medical Officer, Oblenio Bio, Alex Boches, Chief Business Officer, NovalGen, Giovanni Abbadessa, Chief Medical officer, ModeX Therapeutics, Karsten Sauer, Consultant, Karsten Sauer Consulting, Xingfeng bao xingfeng bao, Senior Vice President and Head of Research, GV20 Therapeutics LLC, Max Wang, Business Development Professional, Fapon Biopharma, Jeffrey Jones, Chief Medical Officer, CULLINAN THERAPEUTICS, INC., Patrick Baeuerle, Chief Scientific Advisor and Chairman of Scientific Advisory Board, CULLINAN THERAPEUTICS, INC., Ariel Guo, Chief of Staff and Assistant Chief Operating Officer and Vice President, Corporate Development, Antengene, Zhinan Xia, Founder and Chief Scientific Officer, Abimmune Biotherapeutics, Marvin Gee, Chief Research Officer and Co-Founder, 3T Biosciences, Mike Jones, Search and Evaluation Lead, GI and Inflammation, Strategy and Portfolio Development, Takeda Pharmaceutical, Shinji Okitsu, Head of Research Strategic Collaborations and Partnerships, Sanofi, Anand Giddabasappa, Head and Research Fellow, AMI - Global Discovery, Investigative and Translational Sciences, Pfizer, Yi Yang, Director of Cell and Gene Therapy, Novartis AG, Mike Wan, Senior Manager of Clinical Pharmacology, Gilead Sciences, Mohamed Hassanein, Senior Director of Immunologu, Eli Lilly and Co., Naresh Kumar, Director Bioscience Immunology, AstraZeneca

2nd T-Cell Engager for Autoimmune Disease Summit

Share this event

Sponsored events

Sweat & Spritz: A Fitness & Social Experience at Boston Landing